Osama A Al-masri, MD in Athol, MA - Orthopaedic Surgery

Osama A Al-masri, MD is a Orthopaedic Surgery physician based in Athol, Massachusetts. Osama A Al-masri is licensed to practice in Massachusetts (license number 39031) and his current practice location is 80 Mechanic St, 1:4, Athol, Massachusetts. He can be reached at his office (for appointments etc.) via phone at (978) 249-5668.

NPI number for Osama A Al-masri is 1144216946 and his current mailing address is 80 Mechanic St, 1:4, Athol, Massachusetts. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1144216946.

Contact Information

	Osama A Al-masri, MD
	80 Mechanic St, 1:4, Athol, MA 01331-3534
	(978) 249-5668
	(978) 249-5669

Physician's Profile

Full Name	Osama A Al-masri
Gender	Male
Speciality	Orthopaedic Surgery
Location	80 Mechanic St, Athol, Massachusetts
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1144216946
Provider Enumeration Date: 09/27/2005
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Osama A Al-masri such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1144216946	NPI	-	NPPES
3046621	Medicaid	MA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207X00000X	Orthopaedic Surgery	39031 (Massachusetts)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Osama A Al-masri is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Osama A Al-masri, MD 80 Mechanic St, 1:4, Athol, MA 01331-3534 Ph: (978) 249-5668	Osama A Al-masri, MD 80 Mechanic St, 1:4, Athol, MA 01331-3534 Ph: (978) 249-5668

News Archive

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India.

Poll: Americans' health reform fears eased in January

With President Barack Obama's health care overhaul in limbo, Americans' fears about its effect on them eased in January, according to a poll released as the president tries to revive sweeping Democratic legislation," The Associated Press/MSNBC reports.

Hendra virus treatment to be ready in a few months

Of the dozen people who were exposed to a horse infected with the Hendra virus, 11 have been cleared of the infection by repeated tests on Queensland's Sunshine Coast. These 12 people had first come into contact with the infected horse at Tewantin in May and have since then been subjected to testing to rule out infection with the deadly virus. It is expected that the 12th person will also be cleared soon. Quarantine restrictions were also lifted last month.

In-depth review of current research on the health effects of vitamin D

Despite considerable progress in research to understand the health effects of vitamin D, experts convened by the NIH to review the available data found major gaps in the evidence. The data are strongest in the area of bone health among elderly men and post-menopausal women, suggesting that increased vitamin D intake can improve bone health and prevent falls. For other age groups and health issues, though, it is too early to say conclusively whether more vitamin D might be beneficial.

Osama A Al-masri, MD - Orthopaedic Surgery in Athol, MA